NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 14th May 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Alan Thomas Present for all items
4. Ana Duarte Items 1.1 to 4.3.2
5. Becky Pennington Present for all items
6. Dominic Pivonka Present for all items
7. Dr Andrew Champion Present for all items
8. Dr Craig Buckley Present for all items
9. Dr Ian Bernstein Present for all items
10. Dr Justin Daniels Present for all items
11. Dr Patrick De Barr Present for all items
12. Dr Peter Baker-Gulliver Present for all items
13. Dr Pratheeban Nambyiah Present for all items
14. Hugo Pedder Present for all items
15. Jaqueline Tomlinson Present for all items
16. Mario Ganau Present for all items
17. Min Ven Teo Present for all items
18. Mohamad Farhat Present for all items
19. Professor G.J. Melendez-Torres Present for all items
20. Richard Ballerand Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Rich Diaz, Associate Director Present for all items

Vonda Murray, Project Manager Present for all items

Nigel Gumbleton, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Alexandra Sampson, Heath Technology Assessment Analyst

Items 1.1 to 4.3.2

Victoria Gillis-Elliott, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Mary Hughes, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Sarah Davis, School of Health and Related Research (ScHARR)

Items 1.1 to xx

Jean Hamilton, School of Health and Related Research (ScHARR)

Items 1.1 to xx

Pedro Saramago, Centre for Reviews and Dissemination and Centre for Health Economics – York Items 5.1 to xx

Mark Corbett, Centre for Reviews and Dissemination and Centre for Health Economics – York Items 5.1 to xx

Clinical, Patient & NHS England experts present

Eugene McCloskey, Professor in Adult Bone Diseases, Clinical expert, nominated by Theramex Items 1.1 to 4.1.3

Philippa Russell, Patient expert, nominated by Royal Osteoporosis Society

Items 1.1 to 4.1.3

Alison Smith, Patient expert, nominated by Royal Osteoporosis Society

Items 1.1 to 4.1.3

Lucy Leeman, Consultant Clinical Immunologist, Clinical expert, nominated by NHS England Items 5.1 to 5.1.3

Shuaib Nasser, Consultant in Allergy and Asthma, Clinical expert, nominated by ALK

Items 5.1 to 5.1.3

Helen Evans-Howells, Patient expert, nominated by Anaphylaxis UK

Items 5.1 to 5.1.3

Amena Warner, Patient expert, nominated by Allergy UK Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Fiona MacPherson Smith, Ravi Ramessur, Steve Edwards and Mohit Sharma.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 9th April 2024.

### Appraisal of [Abaloparatide for treating osteoporosis in postmenopausal women [ID882]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10071)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Theramex.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10071).
     3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Alan Thomas (lay), Craig Buckley (cost) and G.J Melendez-Torres (clinical) .
  2. Part 2a – Closed session (members of the public, patient and clinical experts and company were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2 –Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10071>

### Appraisal of [SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11355)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from ALK-Abello.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11355).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Richard Ballerand (lay) Justin Daniels (clinical) and Peter Baker (cost).
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11355>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 11th June and will start promptly at 9am.